APAC Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029
author
Data Bridge Market Research
date
2 years ago
delivery time
1 business day
author
Data Bridge Market Research
date
2 years ago
delivery time
1 business day
Asia-Pacific leber congential amaurosis market is projected to register a CAGR of 3.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029
Market Segmentation:
Asia-Pacific Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Asia-Pacific leber congential amaurosis market are:
• Revolutionized genetic and molecular diagnosis
• Increased rate of consanguinity in some Asian populations
Market Players:
The key market players for Asia-Pacific leber congential amaurosis market are listed below:
• MeiraGTx Limited
• Editas Medicine
• Eluminex Biosciences
• Okuvision
• Astellas Pharma Inc.
• Gyroscope Therapeutics Limited
• SparingVision
• Kubota Pharmaceutical Holdings Co. Ltd.